Literature DB >> 9358202

Excretion of tacrolimus glucuronides in human bile.

I Firdaous1, R K Verbeeck, A Hassoun, J M Langrehr, P E Wallemacq.   

Abstract

Tacrolimus is extensively metabolized by the cytochrome P-450 system. Hepatic metabolic phase I reactions of tacrolimus include mainly demethylation and/or hydroxylation. No valid data have been published on phase II pathways (glucuronide- or sulfo-conjugation). In order to investigate these pathways, different beta-glucuronidase/sulfatase enzyme preparations were used to hydrolyse the conjugates potentially present in human bile extracts. Two analytical methods were used: a non-specific method, MEIA, and a specific combined HPLC/MEIA method. The influence of the extraction pH was investigated. After beta-glucuronidase hydrolysis and extraction at pH 5, tacrolimus concentrations, obtained either from HPLC-MEIA or MEIA, always appeared significantly higher, suggesting the presence of glucuronides in the bile. When the extraction was performed at pH 1.5, only the HPLC-MEIA concentrations appeared higher after hydrolysis. MEIA concentrations obtained before and after hydrolysis were similar. These data are consistent with the fact that glucuronides are extracted at pH 1.5 but not at pH 5 and suggest first that, without hydrolysis, the extracted glucuronides are separated from the tacrolimus fraction in the HPLC-MEIA procedure, and second, that the glucuronides are cross-detected by the monoclonal antibody in the immunoassay. From these data, it is concluded that clues have been found, suggesting the presence in human bile of tacrolimus glucuronides, which cross-react with the monoclonal antibody, provided they are extracted in the sample tested.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358202     DOI: 10.1007/BF03189810

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

1.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro.

Authors:  I Ali Shah; P H Whiting; G Omar; A W Thomson; M D Burke
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes.

Authors:  G Lhoëst; N Maton; R K Verbeeck
Journal:  Drug Metab Dispos       Date:  1993 Sep-Oct       Impact factor: 3.922

4.  Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes.

Authors:  J O Miners; K J Lillywhite; K Yoovathaworn; M Pongmarutai; D J Birkett
Journal:  Biochem Pharmacol       Date:  1990-08-01       Impact factor: 5.858

5.  HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients.

Authors:  I Firdaous; A Hassoun; J B Otte; R Reding; J P Squifflet; T Besse; P E Wallemacq
Journal:  Clin Chem       Date:  1995-09       Impact factor: 8.327

6.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

Authors:  M Sattler; F P Guengerich; C H Yun; U Christians; K F Sewing
Journal:  Drug Metab Dispos       Date:  1992 Sep-Oct       Impact factor: 3.922

7.  In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism.

Authors:  S H Vincent; B V Karanam; S K Painter; S H Chiu
Journal:  Arch Biochem Biophys       Date:  1992-05-01       Impact factor: 4.013

Review 8.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

9.  UDP-glucuronosyltransferase activity toward digitoxigenin-monodigitoxoside. Differences in activation and induction properties in rat and mouse liver.

Authors:  G A Hazelton; C D Klaassen
Journal:  Drug Metab Dispos       Date:  1988 Jan-Feb       Impact factor: 3.922

10.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.

Authors:  K Iwasaki; T Shiraga; H Matsuda; K Nagase; Y Tokuma; T Hata; Y Fujii; S Sakuma; T Fujitsu; A Fujikawa
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

View more
  3 in total

Review 1.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

2.  Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Authors:  Shripad D Chitnis; Ken Ogasawara; Björn Schniedewind; Reginald Y Gohh; Uwe Christians; Fatemeh Akhlaghi
Journal:  Xenobiotica       Date:  2013-01-02       Impact factor: 1.908

3.  Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions.

Authors:  A Bader; T Hansen; G Kirchner; C Allmeling; A Haverich; J T Borlak
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.